Brilique 90mg tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Ticagrelor

Available from:

AstraZeneca UK Ltd

ATC code:

B01AC24

INN (International Name):

Ticagrelor

Dosage:

90mg

Pharmaceutical form:

Tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 02090000; GTIN: 5000455019676

Patient Information leaflet

Patient Information Leaflet
PACKAGE LEAFLET: INFORMATION FOR THE USER
_ _
BRILIQUE 90 MG FILM-COATED TABLETS
ticagrelor
_ _
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Brilique is and what it is used for
2.
What you need to know before you take Brilique
3.
How to take Brilique
4.
Possible side effects
5.
How to store Brilique
6.
Contents of the pack and other information
1.
WHAT BRILIQUE IS AND WHAT IT IS USED FOR
WHAT BRILIQUE IS
Brilique contains an active substance called ticagrelor. This belongs
to a group of medicines called
antiplatelet medicines.
WHAT BRILIQUE IS USED FOR
Brilique in combination with acetylsalicylic acid (another
antiplatelet agent) is to be used in adults
only. You have been given this medicine because you have had:
•
a heart attack, or
•
unstable angina (angina or chest pain that is not well controlled).
It reduces the chances of you having another heart attack, stroke or
dying from a disease related to
your heart or blood vessels.
HOW BRILIQUE WORKS
Brilique affects cells called ‘platelets’ (also called
thrombocytes). These very small blood cells help
stop bleeding by clumping together to plug tiny holes in blood vessels
that are cut or damaged.
However, platelets can also form clots inside diseased blood vessels
in the heart and brain. This can be
very dangerous because:
•
the clot can cut off the blood supply completely; this can cause a
heart attack (myocardial
infarction) or stroke, or
•
the clot can partly block the blood vessels to the heart; this

Summary of Product characteristics

OBJECT 1
BRILIQUE 90 MG FILM COATED TABLETS
Summary of Product Characteristics Updated 24-May-2018 | AstraZeneca
UK Limited
1. Name of the medicinal product
Brilique 60 mg film-coated tablets
Brilique 90 mg film-coated tablets
2. Qualitative and quantitative composition
Brilique 60 mg film-coated tablets
Each film-coated tablet contains 60 mg ticagrelor.
Brilique 90 mg film-coated tablets
Each film-coated tablet contains 90 mg ticagrelor.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Film-coated tablet (tablet).
Brilique 60 mg film-coated tablets
Round, biconvex, pink tablets marked with '60' above 'T' on one side
and plain on the other.
Brilique 90 mg film-coated tablets
Round, biconvex, yellow tablets marked with '90' above 'T' on one side
and plain on the other.
4. Clinical particulars
4.1 Therapeutic indications
Brilique, co-administered with acetylsalicylic acid (ASA), is
indicated for the prevention of
atherothrombotic events in adult patients with
- acute coronary syndromes (ACS) or
- a history of myocardial infarction (MI) and a high risk of
developing an atherothrombotic event (see
sections 4.2 and 5.1).
4.2 Posology and method of administration
Posology
Patients taking Brilique should also take a daily low maintenance dose
of ASA 75-150 mg, unless
specifically contraindicated.
_Acute coronary syndromes _
Brilique treatment should be initiated with a single 180 mg loading
dose (two tablets of 90 mg) and then
continued at 90 mg twice daily.
Treatment with Brilique 90 mg twice daily is recommended for 12 months
in ACS patients unless
discontinuation is clinically indicated (see section 5.1).
_History of myocardial infarction _
Brilique 60 mg twice daily is the recommended dose when an extended
treatment is required for patients
with a history of MI of at least one year and a high risk of an
atherothrombotic event (see section 5.1).
Treatment may be started without interruption as continuation therapy
after the initial one-year treatment
with Brilique 90 mg or other adenosine diph